Evidence map›Paper›PMID 31205531›Full record

ArticleJournal of Cancer2019

Downregulation of DACT-2 by Promoter Methylation and its Clinicopathological Significance in Prostate Cancer.

Shibao Li, Lingyu Yin, Kai Huang, Yao Zhao, Haoliang Zhang, Chenchen Cai, Yinhai Xu, Lingyan Huang, Xiaozhou Wang, Ting Lan and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. P2YActa pharmaceutica Sinica. B · 2025
    Article
  3. The Role of DACT Family Members in Tumorigenesis and Tumor Progression.International journal of biological sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Shibao LiSchool of Medical Technology, Xuzhou Medical University, Xuzhou 221004, China.
Lingyu YinSchool of Medical Technology, Xuzhou Medical University, Xuzhou 221004, China.
Kai HuangDepartment of Urology, Northern Jiangsu People's hospital, Yangzhou 225001 China.
Yao ZhaoSchool of Medical Technology, Xuzhou Medical University, Xuzhou 221004, China.
Haoliang ZhangSchool of Medical Technology, Xuzhou Medical University, Xuzhou 221004, China.
Chenchen CaiSchool of Medical Technology, Xuzhou Medical University, Xuzhou 221004, China.
Yinhai XuDepartment of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
Lingyan HuangSchool of Medical Technology, Xuzhou Medical University, Xuzhou 221004, China.
Xiaozhou WangThe center of functional experiment, Xuzhou Medical University, Xuzhou Jiangsu 221004, China.
Ting LanSchool of Medical Technology, Xuzhou Medical University, Xuzhou 221004, China.
Hongchun LiSchool of Medical Technology, Xuzhou Medical University, Xuzhou 221004, China.
Ping MaSchool of Medical Technology, Xuzhou Medical University, Xuzhou 221004, China.
Xuzhou Medical College · CNNorthern Jiangsu People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DACT-2Gleason scoremethylationprostate cancerTNM staging

Identifiers

PMID31205531
PMCPMC6548005
OpenAlexW2947230556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.